問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Pediatrics

Division of Infectious Disease

CHANGHUA CHRISTIAN HOSPITAL (在職)

更新時間：2024-06-04

邱政洵Chiu, Cheng-Hsun
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

  • chchiu@cgmh.org.tw

Recruiting Trial

23Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

邱政洵

List

65Cases

2017-12-01 - 2019-03-31

Phase II

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus

  • Condition/Disease

    Respiratory Syncytial Viruses

  • Test Drug

    Lumicitabine (JNJ-64041575)

Participate Sites
3Sites

Terminated3Sites

2017-12-15 - 2021-08-25

Phase II

A Long-term Follow-up of Study 64041575RSV2004 to Evaluate the Impact of Lumicitabine (JNJ-64041575) on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection

  • Condition/Disease

    Respiratory Syncytial Virus Infections

  • Test Drug

    Lumicitabine (JNJ-64041575)

Participate Sites
3Sites

Terminated3Sites

2013-03-18 - 2016-11-30

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2021-06-01 - 2023-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2014-09-01 - 2018-09-04

Phase III

A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to NonAdjuvanted Comparator Influenza Vaccine in Children ≥6 to < 72 Months of Age.

  • Condition/Disease

    Vaccines to prevent influenza

  • Test Drug

    aQIV

Participate Sites
3Sites

Terminated2Sites

Study ended1Sites

黃高彬
China Medical University Hospital

Division of Pediatrics

1 3 4 5 6 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB